The therapy of multiple sclerosis with immune-modulating or immunosuppressive drug A critical evaluation based upon evidence based parameters and published systematic reviews

被引：11

作者：

Clerico, Marinella ^{[1
]}

Rivoiro, Chiara ^{[1
]}

Contessa, Giulia ^{[1
]}

Viglietti, Daniela ^{[1
]}

Durelli, Luca ^{[1
]}

机构：

[1] Univ Turin, Dipartimento Sci Clin & Biol, Div Neurol, Osped Univ, Turin, Italy

来源：

CLINICAL NEUROLOGY AND NEUROSURGERY | 2008年 / 110卷 / 09期

关键词：

Multiple sclerosis; Immunomodulatory treatments; Immunosuppressory treatments evidence based medicine; Evidence based medicine; Systematic reviews;

D O I：

10.1016/j.clineuro.2007.10.020

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Today many different drugs are available for treatment of multiple sclerosis (MS). Interferons, glatiramer acetate. mitoxantrone, and natalizumab have been approved by the regulatory authorities of many countries for the treatment of MS. Evidence based medicine (EBM) principles allow physicians to better address the correct treatment for patients. This article aimed to review all the clinical trials on immune-modulating and immunosuppressive drugs on the basis of the EBM principles. Based on the evidence to date interferon beta represents the best therapeutic option, particularly if given at high doses and with Multiple injections per week. Due to its lower efficacy, glatiramer acetate should be used as a second choice in case of intolerable side effects or toxicity of interferon beta. Great efficacy has been demonstrated for mitoxantrone and natalizumab. These drugs should be, however. used with particular attention for their potential toxic effects. (C) 2007 Elsevier B.V. All rights reserved.

引用

页码：878 / 885

页数：8

共 32 条

[1] The revised CONSORT statement for reporting randomized trials: Explanation and elaboration [J].

Altman, DG ;

Schulz, KF ;

Moher, D ;

Egger, M ;

Davidoff, F ;

Elbourne, D ;

Gotzsche, PC ;

Lang, T .

ANNALS OF INTERNAL MEDICINE, 2001, 134 (08) :663-694

[2]

[Anonymous], COCHRANE DATABASE SY, DOI 10.1002/14651858.CD004678

[3] Effects of glatiramer acetate on relapse rate and accumulated disability in multiple sclerosis: meta-analysis of three double-blind, randomized, placebo-controlled clinical trials [J].

Boneschi, FM ;

Rovaris, M ;

Johnson, KP ;

Miller, A ;

Wolinsky, JS ;

Ladkani, D ;

Shifroni, G ;

Comi, G ;

Filippi, M .

MULTIPLE SCLEROSIS, 2003, 9 (04) :349-355

[4] Interferon beta results in immediate reduction of contrast-enhanced MRI lesions in multiple sclerosis patients followed by weekly MRI [J].

Calabresi, PA ;

Stone, LA ;

Bash, CN ;

Frank, JA ;

McFarland, HF .

NEUROLOGY, 1997, 48 (05) :1446-1448

[5] Effect of early interferon treatment on conversion to definite multiple sclerosis:: a randomised study [J].

Comi, G ;

Filippi, M ;

Barkhof, F ;

Durelli, L ;

Edan, G ;

Fernández, O ;

Hartung, HP ;

Seeldrayers, P ;

Sorensen, PS ;

Rovaris, M ;

Martinelli, V ;

Hommes, OR .

LANCET, 2001, 357 (9268) :1576-1582

[6]

DUQUETTE P, 1995, NEUROLOGY, V45, P1277

[7] INTERFERON BETA-1B IS EFFECTIVE IN RELAPSING-REMITTING MULTIPLE-SCLEROSIS - CLINICAL-RESULTS OF A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL [J].

DUQUETTE, P ;

GIRARD, M ;

DESPAULT, L ;

DUBOIS, R ;

KNOBLER, RL ;

LUBLIN, FD ;

KELLEY, L ;

FRANCIS, GS ;

LAPIERRE, Y ;

ANTEL, J ;

FREEDMAN, M ;

HUM, S ;

GREENSTEIN, JI ;

MISHRA, B ;

MULDOON, J ;

WHITAKER, JN ;

EVANS, BK ;

LAYTON, B ;

SIBLEY, WA ;

LAGUNA, J ;

KRIKAWA, J ;

PATY, DW ;

OGER, JJ ;

KASTRUKOFF, LF ;

MOORE, GRW ;

HASHIMOTO, SA ;

MORRISON, W ;

NELSON, J ;

GOODIN, DS ;

MASSA, SM ;

GUTTERIDGE, E ;

ARNASON, BGW ;

NORONHA, A ;

REDER, AT ;

MARTIA, R ;

EBERS, GC ;

RICE, GPA ;

LESAUX, J ;

JOHNSON, KP ;

PANITCH, HS ;

BEVER, CT ;

CONWAY, K ;

WALLENBERG, JC ;

BEDELL, L ;

VANDENNOORT, S ;

WEINSHENKER, B ;

WEISS, W ;

REINGOLD, S ;

PACHNER, A ;

TAYLOR, W .

NEUROLOGY, 1993, 43 (04) :655-661

[8] Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN) [J].

Durelli, L ;

Verdun, E ;

Barbero, P ;

Bergui, M ;

Versino, E ;

Ghezzi, A ;

Montanari, E ;

Zaffaroni, M .

LANCET, 2002, 359 (9316) :1453-1460

[9] Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis [J].

Ebers, GC ;

Rice, G ;

Lesaux, J ;

Paty, D ;

Oger, J ;

Li, DKB ;

Beall, S ;

Devonshire, V ;

Hashimoto, S ;

Hooge, J ;

Kastrukoff, L ;

Krieger, C ;

Mezei, M ;

Seland, P ;

Vorobeychi, G ;

Morrison, W ;

Nelson, J ;

Freedman, MS ;

Chrisie, S ;

Nelson, R ;

Rabinovitch, H ;

Freedman, C ;

Hartung, HP ;

Rieckmann, P ;

Archelos, J ;

Jung, S ;

Weilbach, F ;

Flachenecke, P ;

Sauer, J ;

Hommes, O ;

Jongen, P ;

Brouwer, S ;

McLeod, J ;

Pollard, J ;

Ng, R ;

Sandberg-Wollheim, M ;

Källén, K ;

Nilsson, P ;

Ekberg, R ;

Lundgren, A ;

Jadbäck, G ;

Wikström, J ;

Multanen, J ;

Valjakka, M ;

Carton, H ;

Lissoir, F ;

Declerq, I ;

Vieren, M ;

Peeters, E ;

Dubois, B .

LANCET, 1998, 352 (9139) :1498-1504

[10] Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: A randomised multicentre study of active disease using MRI and clinical criteria [J].

Edan, G ;

Miller, D ;

Clanet, M ;

Confavreux, C ;

LyonCaen, O ;

Lubetzki, C ;

Brochet, B ;

Berry, I ;

Rolland, Y ;

Froment, JC ;

Dousset, V ;

Cabanis, E ;

IbaZizen, MT ;

Gandon, JM ;

Lai, HM ;

Moseley, I ;

Sabouraud, O .

JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 1997, 62 (02) :112-118

← 1 2 3 4 →